NCT00526279已完成不适用
A Prospective, Non-interventional, Observational, Multi-center Trial to Evaluate Compliance and Efficacy in Mono and Combination Treatment of Candesartan Cilexetil(Atacand)/ Candesartan Cilexetil 16mg, Hydrochlorothiazide 12.5mg(Atacand Plus) in Hypertension
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 9,000
- 试验地点
- 1
研究概览
简要总结
To evaluate compliance and patients' satisfaction in mono and combination treatment of Candesartan cilexetil (Atacand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg (Atacand plus) in hypertension.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have consented to participation/data release in this study
- •Patients diagnosed with hypertension and prescribed with atacand/atacand plus by the physician based on clinical decision
排除标准
- •Secondary hypertension requiring therapy other than antihypertensive medication
- •Patients not prescribed with atacand/atacand plus based on safety reasons or any other reason as determined by the physician
- •Women in pregnancy or lactation
- •Patients enrolled in any other studies
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential HypertensionEssential HypertensionNCT02059616HK inno.N Corporation384
终止
4 期
A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic DrugSchizophreniaNCT01592201Janssen Korea, Ltd., Korea13
已完成
2 期
Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and PlaceboObesityHypertensionNCT00282178Umeå University26
已完成
不适用
Assessment of the Satisfaction of Patient Undergoing Opioid Replacement Therapy Toward Their Management in Community PharmacyOpioid-Related DisordersNCT03961789University Hospital, Clermont-Ferrand98
已完成
不适用
APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)Breast CancerNCT00523315AstraZeneca862